Imaging findings and pharmacokinetics of 111-indium ZME-018 monoclonal antibody (MoAb) in malignant melanoma

Conference · Wed May 01 04:00:00 EDT 1985 · J. Nucl. Med.; (United States)

OSTI ID:6795333

Murray, J L; Rosenblum, M; Lamki, L; Haynie, T P; Glenn, H; Jahns, M; Plager, C; Hersh, E M; Unger, M; Carlo, D L

13 patients with metastatic melanoma were studied using 5 mCi of In-111 labeled MoAb ZME-018 which reacts with GP 240 melanoma-associated antigen. The MoAb was infused over 2 h at doses of 2.5 mg (5 pts), 5 mg (5 pts), and 10 mg (3 pts). Total body tomograms and planar spot views with region of interest analysis were performed at 4, 24 and 72 hours post infusion. No adverse side effects were noted. There was rapid distribution to spleen, bone, bone marrow, liver, and testes. Tumor sites could be visualized as early as 24 hours but were more easily seen at 72 hours when the background activity was less. 20 of 46 (43%) previously documented metastases were identified. More sites imaged with increasing concentrations of MoAB, I.E., 25% at 2.5 mg; 67% at 5 mg; 70% at 10 mg. Tumor localization occurred in a significant number of patients especially at MoAb doses above 2.5 mg. In two instances, uptake of 111-In occurred in previously undiagnosed sites. The pharmacokinetics of MoAb were analyzed at each dose level. At the 5 mg dose, the terminal phase half-life for 111-In in plasma was 24.5 +- 2.7 hours. The apparent volume of distribution (Vd) was 4.03 +- 5iota similar to the plasma value, and the calculated clearance rate for 111-In label was 0.0259 + 0.002 ml/kg/min. Mean urinary excretion of 111-In label was 8.7 +- 0.6% of the administered dose over 48 hours after administration. The calculated pharmacokinetic parameters were independent of antibody dose. ZME 018 was cleared more rapidly from plasma, compared to previous studies with P97 antimelanoma MoAb.

• Research Organization: Univ. of Texas M.D. Anderson Hospital, Houston, TX 77030
• OSTI ID: 6795333
• Report Number(s): CONF-850611-
• Conference Information: Journal Name: J. Nucl. Med.; (United States) Journal Volume: 26:5
• Country of Publication: United States
• Language: English

Related Subjects

550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
550602 -- Medicine-- External Radiation in Diagnostics-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANIMAL TISSUES
ANTIBODIES
BIOMEDICAL RADIOGRAPHY
BODY
BONE MARROW
BONE TISSUES
CAT SCANNING
CLEARANCE
COMPUTERIZED TOMOGRAPHY
CONNECTIVE TISSUE
COUNTING TECHNIQUES
DATA ANALYSIS
DIAGNOSTIC TECHNIQUES
DIGESTIVE SYSTEM
DISEASES
DISTRIBUTION
DOSIMETRY
DRUGS
EXCRETION
FUNCTIONS
GLANDS
GONADS
HEMATOPOIETIC SYSTEM
IMAGES
LABELLED COMPOUNDS
LABELLING
LIVER
MALE GENITALS
MEDICINE
MELANOMAS
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
ORGANS
PATIENTS
RADIOISOTOPE SCANNING
RADIOLOGY
RADIOPHARMACEUTICALS
RETENTION FUNCTIONS
SIDE EFFECTS
SPLEEN
TESTES
TISSUE DISTRIBUTION
TISSUES
TOMOGRAPHY
UPTAKE